Dr. Stephen Wilmarth, chairman of the ophthalmic development committee at NovaBay Pharmaceuticals, discusses synthetic antimicrobials called Aganocides that may deliver the same or better efficacy than antibiotics without triggering antibiotic-resistance.

Financial Disclosures: Dr. Arbisser discloses that she receives lecture fees from Alcon Laboratories and grant support from the See Life Clearly Foundation. Dr. Wilmarth discloses that he receives consulting fees from and is an equity owner of NovaBay Pharmaceuticals.